



Prolia™, Xgeva® (denosumab) – New Warning

- On January 31, 2017, the [FDA approved](#) a new update to the *Warnings and Precautions* section of the [Prolia \(denosumab\)](#) and [Xgeva \(denosumab\)](#) drug labels regarding the risk of multiple vertebral fractures following discontinuation of denosumab treatment.
- Per Amgen, the same safety update applies to Xgeva; however, an updated drug label is not yet available.
- Prolia is indicated for the following:
 - Treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy
 - Treatment to increase bone mass in men with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy
 - Treatment to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for non-metastatic prostate cancer
 - Treatment to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer
- Xgeva is indicated for the following:
 - Prevention of skeletal-related events in patients with bone metastases from solid tumors
 - Xgeva is not indicated for the prevention of skeletal-related events in patients with multiple myeloma
 - Treatment of adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity
 - Treatment of hypercalcemia of malignancy refractory to bisphosphonate therapy
- Following discontinuation of Prolia treatment, fracture risk increases, including the risk of multiple vertebral fractures. Cessation of Prolia treatment results in markers of bone resorption increasing above pretreatment values then returning to pretreatment values 24 months after the last dose of Prolia. In addition, bone mineral density returns to pretreatment values within 18 months after the last injection.
 - New vertebral fractures occurred as early as 7 months (on average 19 months) after the last dose of Prolia. Prior vertebral fracture was a predictor of multiple vertebral fractures after Prolia discontinuation.
 - An individual's benefit/risk should be evaluated before initiating treatment with Prolia.
 - If Prolia treatment is discontinued, transitioning to an alternative antiresorptive therapy should be considered.
- Similar updates were made to the Prolia Medication Guide.

- An additional update to the Prolia drug label includes the removal of information regarding Amgen's Pregnancy Surveillance Program from the Pregnancy subsection of the *Use in Specific Populations* section.



OptumRx[®] specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum[®] company — a leading provider of integrated health services. Learn more at optum.com.

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews[®] is published by the OptumRx Clinical Services Department.

©2017 Optum, Inc. All rights reserved.